A Post Authorization Registry Study of Participants Treated With LEQEMBI
Key facts
- Where
- Calgary, Edmonton, Gatineau, Greenfield Park, Kingston, London, Mississauga, Montreal, Ottawa, Peterborough, Québec, Toronto, Vancouver és Victoria, KanadaSee the 17 sites
Where in Kanada
- University of Calgary - Hotchkiss Brain InstituteCalgary, KanadaToborzás még nem indult
- University of Alberta, Geriatric DivisionEdmonton, KanadaToborzás még nem indult
- Clinique Neuro-OutaouaisGatineau, KanadaToborzás még nem indult
- MOCAGreenfield Park, KanadaTaking people
- Kingston HHC (Queen University)Kingston, KanadaToborzás még nem indult
- Parkwood Hospital - LondonLondon, KanadaToborzás még nem indult
- Trillium HospitalMississauga, KanadaToborzás még nem indult
- IUGMMontreal, KanadaToborzás még nem indult
- McGill University, Douglas Mental HealthMontreal, KanadaToborzás még nem indult
- Bruyère InstituteOttawa, KanadaToborzás még nem indult
- Kawartha CenterPeterborough, KanadaTaking people
- CHU de Québec-Université Laval Research CenterQuébec, KanadaToborzás még nem indult
- Sunnybrook HospitalToronto, KanadaToborzás még nem indult
- Toronto Memory ProgramToronto, KanadaTaking people
- Toronto Western HospitalToronto, KanadaToborzás még nem indult
- University of British Columbia - CARDVancouver, KanadaToborzás még nem indult
- UBC Victoria - Neil and Susan Manning Cognitive Health InitiativeVictoria, KanadaToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eisai Limited
- Trial code
- NCT07762092
- Record updated
- 2026. november 5.
- Original description
To describe the incidence and severity of known adverse events, including amyloid-related imaging abnormalities-edema (ARIA-E), ARIA microhemorrhage and hemosiderin deposit (ARIA-H), and intracerebral hemorrhage greater than 1 cm in diameter in participants treated with LEQEMBI during routine clinical practice, summarizing the data overall and by apolipoprotein E4 variant (APOE4) genotype, concomitant antithrombotic therapy, and baseline magnetic resonance imaging (MRI) findings (comorbid cerebral amyloid angiopathy [CAA]).Read full original descriptionShow less
Post Authorization Registry Study of Patients Treated With LEQEMBI
To describe the incidence and severity of known adverse events, including amyloid-related imaging abnormalities-edema (ARIA-E), ARIA microhemorrhage and hemosiderin deposit (ARIA-H), and intracerebral hemorrhage greater than 1 cm in diameter in participants treated with LEQEMBI during routine clinical practice, summarizing the data overall and by apolipoprotein E4 variant (APOE4) genotype, concomitant antithrombotic therapy, and baseline magnetic resonance imaging (MRI) findings (comorbid cerebral amyloid angiopathy [CAA]).
The secondary purpose of this study is,
To describe progression to the next stage of Alzheimer's Disease (AD), stratified by ARIA and intracerebral hemorrhage greater than 1 cm.
To describe previously unknown adverse events related to the long-term safety of LEQEMBI in routine clinical practice, which were not identified in clinical development, as assessed by serious suspected adverse reactions, adverse reactions leading to discontinuation of LEQEMBI treatment, and deaths that occur within 30 days of discontinuation of LEQEMBI treatment (regardless of causality).
To describe drug utilization of LEQEMBI and to assess the effectiveness of risk minimization measures in routine clinical practice.
Inclusion: Participants with Alzheimer's Disease who are prescribed LEQEMBI in Canada.
Exclusion: None.